The light of hope in the complex stratification of breast cancer, Her2 positive breast cancer is of great concern because of its aggressive nature and poor prognosis. The emergence of intensive assistive treatment has given new hope and light to such patients. HeR2, the human skin growth factor receptor 2, when over-expression of HeR2 protein on the surface of breast cancer cells leads to rapid cell proliferation, increased invasive capacity and increased vulnerability to diversion, thus posing serious challenges to the survival of patients. Enhanced assistive treatment, in turn, aims to further reduce the risk of relapse by means of more active and effective means, and to extend the patient ‘ s life without illness and total survival.
Enhanced assistive treatment is usually performed after the operation, with a combination of treatments. Among them, anti-HER2 targets play a key role in the treatment. The first target drug approved for HeR2 positive breast cancer treatment is the trato-chorus resistance, which works precisely on the HeR2 receptor, disrupts its signal transmission path, like placing a “suspension button” on the growth signal of the cancer cell to inhibit the growth and spread of the tumor cell. The introduction of Pato-Choose has further refined the two-target treatment model, which, when used in a combination with a tuto-Choto-Choose, can be used to double-block Her2 access from different target points, creating synergies and significantly improve treatment effectiveness. chemotherapy is also an important component of intensive assistive treatment. The use of chemotherapy drugs such as Dosipetha and Viscorol has made it possible to kill tumour cells extensively and to control small residuals, reducing the risk of tumour recurrence and transfer. When applied in conjunction with target-oriented treatment, chemotherapy enhances the overall treatment and creates a full-scale encirclement of cancer cells.
Assistive treatment is not a one-time event, and it lasts longer than usual for about a year. During this period, patients need to work closely with the doctor ‘ s monitoring and evaluation, and regular examinations, including cardiac function checks, oncological markers and video-testing, are conducted to detect possible adverse effects in a timely manner and to adjust treatment programmes. Although enhanced assistive treatment may have some side effects, such as heart toxicity, bone marrow inhibition, gastrointestinal reaction etc., the doctor will prevent and treat the patient as much as possible according to his or her circumstances. A large number of clinical research data show that intensive support treatment for positive breast cancer in Her2 has significantly improved the patient ‘ s prognosis. Compared to purely traditional assisted treatment, the risk of relapse of patients receiving intensive assistive treatment has been significantly reduced and the survival rate has increased significantly, resulting in many patients being given a long-term chance of being able to return to normal life and work. For persons with positive breast cancer, intensive care is a difficult but promising battle. Through the combined advantage of multiple means, such as targeted treatment and chemotherapy, it has built a solid bridge for patients to repel the disease and regain their health. In the future, as medical research continues in depth and as new treatment drugs continue to be developed, it is believed that the treatment of positive breast cancer in Her2 will lead to a much more visible breakthrough in the light of hope for more patients.
Breast cancer
